Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06929481 · ClinicalTrials.gov registry record · NA
Screening With a DNA Blood Test to Address Colorectal Cancer Inequities
A NA study, sponsored by University of California, San Diego.
- Active
- Registry status
- NA
- Development phase
- 340
- Enrollment target
NCT06929481 is a NA study that is active but no longer recruiting, run by University of California, San Diego. The registered enrollment target is 340 participants.
The verdict
NCT06929481, a NA study, is active but no longer recruiting, sponsored by University of California, San Diego.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 340 participants
- Enrollment target
Study Summary
Colorectal cancer (CRC) screening participation is suboptimal and associated with inequities in CRC outcomes by race/ethnicity and socioeconomic position. A novel, cell free DNA (cfDNA) blood test has potential to increase participation, but has not been studied in groups at highest risk for adverse CRC outcomes. Among patients age-eligible for colorectal cancer screening, not up-to-date, we propose a 2-arm, pragmatic, randomized controlled trial comparing offers of standard screening options (at home fecal immunochemical test (FIT) or colonoscopy) vs. offers of expanded options (at home FIT, colonoscopy, or in clinic cfDNA plus at home FIT), set at a large Federally Qualified Health Center serving individuals at increased risk for inequities in CRC outcomes. Results will inform guideline and policy makers on whether cfDNA should be supported as a screening option, and support planning for a large-scale trial examining impact of a cfDNA option for screening on CRC and advanced neoplasia detection.
Interventions
- DEVICE Cell free DNA (cfDNA) blood test
- OTHER At home Fecal Immunochemical Test (FIT) or Colonoscopy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2026-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06929481
The ClinicalTrials.gov registry entry for NCT06929481 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cell free DNA (cfDNA) blood test is the first listed.
NCT06929481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06929481 about?
NCT06929481 is a clinical study titled "Screening With a DNA Blood Test to Address Colorectal Cancer Inequities". Colorectal cancer (CRC) screening participation is suboptimal and associated with inequities in CRC outcomes by race/ethnicity and socioeconomic position. A novel, cell free DNA (cfDNA) blood test has potential to increase participation, but has not been studied in groups at highest risk for adverse...
What is the current status of trial NCT06929481?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 340 participants. The study started on 2025-04-28. Estimated completion is 2026-07.
What interventions are being tested in trial NCT06929481?
The interventions under investigation include: Cell free DNA (cfDNA) blood test (DEVICE), At home Fecal Immunochemical Test (FIT) or Colonoscopy (OTHER).
Who is sponsoring clinical trial NCT06929481?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.